1-Imidazol-1-yl-4,4-dimethyl-pentan-3-one | 95546-28-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-Imidazol-1-yl-4,4-dimethyl-pentan-3-one
• 英文别名: 1-Imidazol-1-yl-4,4-dimethylpentan-3-one
• CAS: 95546-28-4
• 化学式: C₁₀H₁₆N₂O
• 分子量: 180.25
• InChiKey: FGZCQDHKXRQQGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  咪唑 、 1-(dimethylamino)-4,4-dimethylpentan-3-one 以 xylene 为溶剂， 反应 48.0h， 以50%的产率得到1-Imidazol-1-yl-4,4-dimethyl-pentan-3-one
  参考文献：
  名称：

  Montignoul, Claude; Richard, Marie-Josee; Vigne, Christian, Journal of Heterocyclic Chemistry, 1984, vol. 21, p. 1489 - 1497

  摘要：

  DOI：

文献信息

• Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
  申请人：SHY Therapeutics LLC

  公开号：US10588894B2

  公开（公告）日：2020-03-17

  Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.

  本文提供了通过化合物与 Ras 超家族蛋白（在某些情况下包括 K-Ras 及其突变体）的 GTP 结合结构域结合，治疗涉及 Ras 超家族信号异常的癌症、炎症性疾病、rasopathies 和纤维化疾病的方法和组合物，以及检测此类组合物的新方法。
• MONTIGNOUL, C.;RICHARD, M. -J.;VIGNE, CH.;GIRAL, L., J. HETEROCYCL. CHEM., 1984, 21, N 5, 1489-1497
  作者：MONTIGNOUL, C.、RICHARD, M. -J.、VIGNE, CH.、GIRAL, L.

  DOI：——

  日期：——
• COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE
  申请人：SHY Therapeutics LLC

  公开号：US20190022074A1

  公开（公告）日：2019-01-24

  Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
• METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
  申请人：DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH

  公开号：US20190070178A1

  公开（公告）日：2019-03-07

  The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
• METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES
  申请人：Dalcor Pharma UK Ltd., Leatherhead, Zug Branch

  公开号：US20210236442A1

  公开（公告）日：2021-08-05

  The invention provides compositions and methods useful for delaying occurrence of new-onset type 2 diabetes, slowing progression of type 2 diabetes, treating type 2 diabetes, and slowing progression of a complication of type 2 diabetes.